Who are CDK4/6i's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): CDK 4/6 inhibitors, (CDK)4/6 inhibitor, Kisqali, Ibrance, Palbociclib, Abemaciclib + Fulvestrant.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cdk4-6i.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

CDK4/6i — Competitive Intelligence Brief

CDK4/6i (CDK4/6i) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CDK4/6 inhibitor. Area: Oncology.

phase 3 CDK4/6 inhibitor CDK4, CDK6 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

CDK4/6i (CDK4/6i) — Hoffmann-La Roche. CDK4/6 inhibitors block cyclin-dependent kinases 4 and 6, which prevents phosphorylation of the retinoblastoma protein and halts cell cycle progression in G1 phase.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CDK4/6i TARGET	CDK4/6i	Hoffmann-La Roche	phase 3	CDK4/6 inhibitor	CDK4, CDK6
CDK 4/6 inhibitors	CDK 4/6 inhibitors	Region Örebro County	phase 3	CDK 4/6 inhibitor	CDK4, CDK6
(CDK)4/6 inhibitor	(CDK)4/6 inhibitor	Tianjin Medical University Cancer Institute and Hospital	phase 3	CDK4/6 inhibitor	CDK4, CDK6
Kisqali	ribociclib	Novartis	marketed	CDK4/6 inhibitor; aromatase inhibitor	Cyclin-dependent kinase (CDK) 4 and 6; aromatase enzyme	2017-01-01
Ibrance	Palbociclib	Pfizer	marketed	CDK4/6 inhibitor	Cyclin-dependent kinases 4 and 6 (CDK4/6)	2015-01-01
Palbociclib	palbociclib	Pfizer Inc.	marketed	CDK4/6 inhibitor	Cyclin-dependent kinases 4 and 6 (CDK4/6)
Abemaciclib + Fulvestrant	Abemaciclib + Fulvestrant	Prof. Wolfgang Janni	marketed	CDK4/6 inhibitor + estrogen receptor antagonist	CDK4/6 and estrogen receptor (ER)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CDK4/6 inhibitor class)

AstraZeneca · 1 drug in this class
Centre Leon Berard · 1 drug in this class
Draig Therapeutics Ltd · 1 drug in this class
Fujian Cancer Hospital · 1 drug in this class
GBG Forschungs GmbH · 1 drug in this class
GERCOR - Multidisciplinary Oncology Cooperative Group · 1 drug in this class
Hoffmann-La Roche · 1 drug in this class
Institut Bergonié · 1 drug in this class
Jiangsu Simcere Pharmaceutical Co., Ltd. · 1 drug in this class
Kartos Therapeutics, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CDK4/6i — Competitive Intelligence Brief. https://druglandscape.com/ci/cdk4-6i. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab